JGC
DNTH icon

J. Goldman & Co’s Dianthus Therapeutics DNTH Stock Holding History

J. Goldman & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,716
Closed -$648K – 759
2026
Q1 		$648K Buy
+7,716
New +$447K 0.02% 479

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

J. Goldman & Co's DNTH Position: Q2 2026 in Review

J. Goldman & Co sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 7,716 shares — an estimated $648K sold.

J. Goldman & Co first reported a position in DNTH in Q1 2026 and held it in 1 quarter. The position peaked at $648K in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • J. Goldman & Co reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 7,716 Dianthus Therapeutics shares in Q2 2026, an estimated $648K.
  • J. Goldman & Co first reported a position in Dianthus Therapeutics in Q1 2026 and held it in 1 quarter.
  • J. Goldman & Co's Dianthus Therapeutics position peaked at $648K in Q1 2026.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.